Safety Assessment of *Lactobacillus paracasei* IBRC-M 11110 in Wistar Rats: A Subacute 28-Day Toxicity Study

**ABSTRACT**

**Background and objectives:** Safety is a key criterion for assessment of probiotics. The objective of this study was to evaluate safety of a new Iranian *Lactobacillus paracasei* IBRC-M 11110 strain as a candidate probiotic.

**Methods:** Eighteen male and 18 female Wistar rats were divided into two experimental and a control group. The experimental groups received the bacterium at two doses of $6 \times 10^8$ CFU/day and $6 \times 10^9$ CFU/day for 28 days through oral gavage. The control groups received normal saline. On day 29, blood, serum and tissue samples were taken for analysis.

**Results:** Administration of the bacterium did not affect the general health and body weight of the rats during the study period. No significant change was observed in the blood parameters of rats in the experimental groups except for a significant decrease in mean corpuscular volume and mean corpuscular hemoglobin of male rats. Serum analysis showed a significant increase in the alanine transaminase and a significant decrease in aspartate transaminase in the experimental groups of male and female rats, respectively. In both male and female rats, a significant decrease in urea and a significant increase in creatinine were observed in the experimental groups. However, the above parameters were all within the normal range. Histopathological analysis of liver and kidney tissues also showed no abnormality.

**Conclusion:** The results confirm that *L. paracasei* IBRC-M 11110 was safe in the subacute toxicity test in Wistar rats.

**Keywords:** *Lactobacillus paracasei*, Toxicity tests, Rats, Safety.
INTRODUCTION

Some microorganisms including various bacteria and yeasts species are known as probiotics (1, 2). According to the World Health Organization (WHO), probiotics are live microorganisms with beneficial health effects if used in sufficient amounts (3). Probiotics can contribute to food digestion, production of vitamins and antibiotics and improvement of immune functions (4). Moreover, studies on the use of probiotics for the prevention or treatment of diseases have reported promising results (5-11). Considering these beneficial effects, the use of probiotics is on the rise. Nowadays, many pharmaceuticals as well as functional foods contain probiotics (12). Therefore, researchers are interested in introducing new strains of probiotics as the beneficial effects are strain-dependent. One of the most important features of a probiotic is its safety. In this regard, the WHO has developed guidelines for the evaluation of probiotics safety (13).

Lactobacillus is one of the most important genera of probiotics. Lactobacilli belong to the lactic acid bacteria (LAB) group. These gram-positive and catalase-negative cocci can tolerate low pH (14). Various species of lactobacilli are generally recognized as safe (GRAS). However, the consumption of some LAB species may lead to diseases such as bacteremia, endocarditis and abscesses (15-18). Lactobacillus paracasei IBRC-M 11110 is a lactic acid-producing Iranian strain. The bacterium has been isolated from dairy products and is considered as a candidate probiotic. To our knowledge, there is no information about the safety of this Lactobacillus strain in the literature. Therefore, the purpose of the present study was to evaluate the safety of L. paracasei IBRC-M 11110 in Wistar rats.

MATERIALS AND METHODS

L. paracasei IBRC-M 11110 was purchased from the Iranian Genetic Resource Center (Tehran, Iran). The bacterial strain was cultured in MRS broth (QUELAB LABORATORIES INC, Canada) at 37 °C for 48 hours. The bacterial culture was then centrifuged at 5000 × g for 10 minutes. The precipitate was washed three times with physiological serum. To make bacterial suspensions, normal saline was used as diluent. Then, bacterial suspensions were prepared at densities of 6 × 10⁸ and 6 × 10⁹ colony-forming unit (CFU). The suspensions were freshly prepared every day, just before being fed to the animals through a gavage needle.

In this research, 18 male and 18 female Wistar rats weighing between 220-250 g were enrolled. The rats were obtained from the animal house of Urmia University (Iran) and transported to the University of Maragheh. At first, the animals were subjected to a 7-day adaptation period. Animal maintenance and experiments were conducted in standard conditions: temperature of between 22 - 25 ºC, free access to water and standard rodents’ pellets and a circadian rhythm with 12-12 light/dark cycles. The ethics committee of the University of Maragheh approved the experimental protocols (UM-2019-number 24). The animals were divided randomly to six groups each containing six animals. This study was conducted according to the Organization for Economic Cooperation and Development (OECD) guidelines (test no. 407) that has been adopted in October 2008. According to this guideline, animals receive one dose of the substance of interest, daily, for 28 days. Overall, four experimental groups (two from each gender) received 6 × 10⁸ and 6 × 10⁹ CFU of bacteria by oral gavage and a basal diet (BD) for 28 consecutive days. In the same period, the control groups received only the basal diet and 100 µl of sterile saline via oral gavage. In the subacute oral toxicity test, general observations were carried out to find any changes in the appearance or behavior of the rats. The body weight of the rats was measured on days 7, 14, 21 and 28. Moreover, the level of food and water consumption was monitored during the 28-day period.

At the end of the experiment, after 12 to 14 hours of fasting, the animals were anesthetized with ketamine (100 mg/kg) and xylazine (20 mg/kg). Then, blood, serum and tissue samples were taken for hematological, biochemical and histopathological evaluations, respectively. The blood samples were analyzed using an automated analyzer (Selectra XL, Vital scientific, Netherlands) to determine the following parameters: hemoglobin (Hb), white blood cell count (WBC), red blood cell count (RBC), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), mean corpuscular hemoglobin...
RESULTS
No mortality occurred during the 28-day period.
In addition, no change in the skin, fur, eyes, mucous membranes and secretions was observed. On the behavioral aspects, no change associated with the treatments was observed.
Overall, the administration of different doses of bacteria to the rats induced no considerable morbidity or mortality in the animals. Daily consumption of food and water did not change significantly in the study groups. Moreover, no significant difference was observed in the mean weight of rats on days 7, 14, 21 and 28. Table 1 shows the effects of different doses of *L. paracasei* IBRC-M 11110 on the blood parameters.

No statistically significant difference in the blood parameters was observed between the female rats in the experimental groups and the control group. Male rats in the experimental groups had significantly lower MCV and MCH levels than those in the control group. Other blood parameters did not differ significantly between male rats in the experimental and control groups.

![Figure 1](image1.png)

**Figure 1** - Effect of *L. paracasei* IBRC-M 11110 consumption on structural features of liver tissues following hematoxylin and eosin staining (images were taken under 400X magnification). Both male and female had normal hepatic tissue, and Scale bar = 30 μm. Hepatocytes (H), Sinusoids (S), Central vein (CV), Proximal (P), Glomerulus (G), Distal (D), Urinary space (US).
The effects of different doses of *L. paracasei* (IBRC-M 11110) on the biochemical parameters of rats are shown in table 2. In male rats, there was no significant difference in the concentrations of AST and ALP between the control and the experimental groups. However, male rats receiving $6 \times 10^9$ CFU of *L. paracasei* had significantly higher level of ALT compared to the respective control group. In female rats, AST decreased significantly in in the animals receiving the lower dose of bacteria. In both sexes, urea decreased significantly and creatinine level increased significantly in the experimental groups.

After 28 days of bacteria administration, no histological abnormality in the liver and kidney tissues was observed in the experimental groups compared to the respective control groups. Liver lobules had normal structure (Figure 1). Similarly, the renal tissue showed no anomaly and the glomeruli as well as distal and proximal tubules had normal appearance (Figure 2).

**DISCUSSION**

The objective of the present research was to evaluate the safety of oral administration of *L. Paracasei* IBRC-M 11110 in rats. The 28-day oral administration of the bacterium had no significant toxic effect on both male and female Wistar rats. During the 28-day study period, the rats had a healthy appearance and normal behavior. An indicator of general health status of animals in toxicity studies is the change in body weight. A significant decrease in the body weight of animals may be due to some adverse toxic effects including loss of appetite, diarrhea and dehydration. Therefore, one of the reasons for the lack of the toxicity of the bacterium in the rats was the normal weight change of the experimental animals during the study period (20).

Toxic doses of xenobiotics can alter blood parameters (21). Therefore, these blood biomarkers are good indices for assessment of physiological status in animals. Changes in hematological parameters may be an indication of inflammation or infection in the body. On the other hand, the increase in ALT, AST, ALP, urea and creatinine may indicate a problem in the liver or kidney (21). In the present study, no significant difference was observed in the hematological parameters of the animals fed with *L. paracasei* IBRC-M 11110 except for a decrease in the amount of MCV and MCH in male rats. MCV is a biomarker showing the size of erythrocytes. Low and high MCV indicate the presence of microcytic and macrocytic erythrocytes in blood, respectively. MCH represents the mean amount of hemoglobin in a single erythrocyte. Both low MCV and MCH may indicate microcytic anemia. However, in our study, the
level of these parameters was in the normal range, indicating that the bacterium had no adverse effects on the volume or hemoglobin content of erythrocytes. In a similar study, it was found that administration of different doses of *Lactobacillus fermentum* PL9005 for 28 days had no major effect on hematological parameters (22).

In another study, administration of *Lactobacillus casei* reduced MCV in the experimental groups compared to the control group (23).

### Table 1 - Effect of *L. paracasei* IBRC-11110 on blood parameters

*P* < 0.05 compared with control group

<table>
<thead>
<tr>
<th>Group</th>
<th>WBC (×10^3/µL)</th>
<th>Lym (%)</th>
<th>RBC (×10^6/µL)</th>
<th>HGB (g/dL)</th>
<th>HCT (%)</th>
<th>MCV (fL)</th>
<th>MCH (pg)</th>
<th>MCHC (g/dL)</th>
<th>PLT (×10^3/µL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>7.7±3.1</td>
<td>74.3±5.6</td>
<td>8±0.15</td>
<td>13±0.39</td>
<td>42±0.71</td>
<td>54±0.45</td>
<td>18.8±0.18</td>
<td>32.40±0.18</td>
<td>850±86</td>
</tr>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>4.89±0.8</td>
<td>69±3.7</td>
<td>6.8±0.2</td>
<td>12.8±0.15</td>
<td>39.1±0.74</td>
<td>538±1</td>
<td>17.6±0.22</td>
<td>32.4±0.5</td>
<td>856±41.4</td>
</tr>
<tr>
<td>Male</td>
<td>8.32±0.9</td>
<td>70.4±7.5</td>
<td>8.21±0.26</td>
<td>13.2±0.48</td>
<td>41.5±1.48</td>
<td>50.4±0.82</td>
<td>16±0.38</td>
<td>31.8±0.31</td>
<td>868±48</td>
</tr>
<tr>
<td>1×10^8 CFU</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>3.87±1.38</td>
<td>65.6±5.8</td>
<td>7.17±0.17</td>
<td>12.6±0.17</td>
<td>38.4±0.2</td>
<td>53.7±1.36</td>
<td>17.6±0.31</td>
<td>32.8±0.39</td>
<td>737.7±97.7</td>
</tr>
<tr>
<td>Male</td>
<td>8.16±1.3</td>
<td>78.1±1.1</td>
<td>8.2±0.1</td>
<td>13.3±0.24</td>
<td>41.1±0.67</td>
<td>50.9±0.59</td>
<td>16.5±0.22</td>
<td>32.3±0.22</td>
<td>758±40.4</td>
</tr>
<tr>
<td>1×10^7 CFU</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>5.7±0.9</td>
<td>76.2±1.1</td>
<td>7±0.15</td>
<td>12.18±0.4</td>
<td>37.3±0.83</td>
<td>52.9±0.62</td>
<td>17.34±0.29</td>
<td>32.74±0.4</td>
<td>791.8±59.9</td>
</tr>
</tbody>
</table>

### Table 2 - Effect of *L. paracasei* IBRC-11110 on biochemical parameters

<table>
<thead>
<tr>
<th>Group</th>
<th>ALP (U/L)</th>
<th>ALT (U/L)</th>
<th>AST (U/L)</th>
<th>Urea (mg/dl)</th>
<th>Creatinine (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>867±100</td>
<td>55±5</td>
<td>128±12.1</td>
<td>39±2</td>
<td>0.74±0.2</td>
</tr>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>6±62.619</td>
<td>80.6±16.4</td>
<td>± 15.8±150.8</td>
<td>47.1±1.9</td>
<td>0.76±0.16</td>
</tr>
<tr>
<td></td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>692.4±337.8</td>
<td>67±10.8</td>
<td>109.4±10.5</td>
<td>29.8±2.2</td>
<td>0.8±0.4</td>
</tr>
<tr>
<td>1×10^8 CFU</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>462±123.8</td>
<td>68±8.8</td>
<td>84.2±51</td>
<td>32.5±2</td>
<td>0.87±0.5</td>
</tr>
<tr>
<td></td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>996.5±165.4</td>
<td>78.6±15.7</td>
<td>121.6±15.1</td>
<td>28.3±3.9</td>
<td>0.84±0.3</td>
</tr>
<tr>
<td>1×10^7 CFU</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>566.8±146.3</td>
<td>68.8±10.9</td>
<td>104±5</td>
<td>27.6±1.8</td>
<td>0.89±0.8</td>
</tr>
</tbody>
</table>

*Medical Laboratory Journal, Sep-Oct, 2021; Vol 15: No 5*
These discrepancies in the results may be related to the effects of gender or the difference in the type of strains used in the experiments. Similar to a previous study (24), the administration of the bacterium did not significantly stimulate the immune system. We measured levels of AST, ALT and ALP to evaluate effect of the bacterium on liver function. In case of liver damage, the serum level of these enzymes increases (25). Unlike ALT, which is mainly found in the liver, AST is found in many other tissues, including the heart, kidneys and brain. Hence, the elevation of AST in the serum is a less specific indicator for liver damage. ALP is present in the liver, bones, placenta, intestines and stomach. Increased ALP activity indicates a dysfunction of the biliary system. ALP may also increase in all types of liver diseases (26). In the present study, the level of ALT and AST increased significantly in the experimental groups of male and female rats, respectively. However, the findings do not necessarily indicate liver damage since the level of these enzymes was still in the normal range. Previous research has shown that the use of some lactobacilli in food had different effects on liver enzymes. In a study on combined administration of several lactobacilli (L. rhamnosus + L. rhamnosus + L. plantarum), ALT levels reduced compared to the control group (27). In another study, a combination of two probiotics (L. casei and L. paracasei) increased the level of ALT compared to the control group (28).

In clinical practice guidelines, determination of serum urea and creatinine concentrations is a good indicator of renal function. Urea is an excretory substance that is filtered by kidney glomeruli and excreted through urine (29). Similarly, creatinine is a waste product that is produced through the breakdown of creatinine phosphate in muscle cells (30). In our study, urea concentration decreased significantly after 28 days of L. paracasei IBRC-M 11110 administration. This is in line with findings of a study on the effects of daily probiotics consumption on urea of chronic kidney patients (31). On the other hand, the high level of creatinine in this study may indicate kidney damage. However, creatinine was in the reference range, so the potential risk of kidney damage induced by the bacterium is minimal. Moreover, analysis of the liver and kidney tissue sections showed no abnormal pathological change. The findings support the results of serum analysis for lack of organ-related toxicity following the L. paracasei consumption.

CONCLUSION
In the present subacute toxicity study, administration of L. paracasei IBRC-M 11110 at doses of 1 × 10⁸ and 1 × 10⁹ CFU/day was safe and did not induce toxic effects on Wistar rats. However, further research is needed to confirm safety of this bacterium as a probiotic.

ACKNOWLEDGEMENTS
The authors would like to thank the staff of University of Maragheh and Urmia University.

CONFLICT OF INTEREST
The authors declare that there is no conflict of interest.

REFERENCES


18. Naqvi SSB, Nagendra V, Hofmeyr A. Probiotic related Lactobacillus rhamnosus endocarditis in a patient with liver cirrhosis. IDCases. 2018;18.13 [View at Publisher] [DOI:10.1016/j.idcr.2018.e00439] [PubMed] [Google Scholar]


How to Cite: